Carfilzomib improves OS for rrMM patients over bortezomib in latest ENDEAVOR update

Positive results we announced today from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial, with the study meeting the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mAUNz2
via IFTTT